Inozyme Pharma, Inc.
INZYDelisted Jul 1, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001693011
Inozyme Pharma, Inc. was delisted on Jul 1, 2025; its insiders filed their last Form 4 on Jul 3, 2025; 87 institutions reported holding it in 13F filings for Q2 2025, worth $202.3M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 87
- Q2 2025, −10 vs. previous quarter
- 13F value
- $202.3M
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding INZY, Q2 2025
No superinvestor reported holding INZY at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by Inozyme Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 (view filing) | Apr 2 | 1 day | Treco Douglas ACEO & Chairman | SSale | −8.82K | $0.89 | −$7.85K | −17.7%41.0K after | |
| Apr 3, 2024 (view filing) | Apr 2 | 1 day | Treco Douglas ACEO | SSale | −7.52K | $6.94 | −$52.2K | −26.7%20.7K after | |
| Aug 3, 2023 (view filing)8:13 PM ET | Aug 1 | 2 days | Pivotal bioVenture Partners Fund I, L.P. and 2 othersDirector | PPurchase | +833.3K | $4.80 | +$4.00M | +112.9%1.57M after | 2 lotsDuplicate filing |
| Aug 3, 2023 (view filing) | Aug 1 | 2 days | Hopfner Robert LorneDirector | PPurchase | +833.3K | $4.80 | +$4.00M | +112.9%1.57M after | 2 lots |
| May 15, 2023 (view filing) | May 11-12 | 4 days | Hopfner Robert LorneDirector | PPurchase | +447.9K | $6.36 | +$2.85M | +13.9%3.66M after | 2 lots |
| Mar 30, 2023 (view filing) | Mar 29 | 1 day | Hopfner Robert LorneDirector | PPurchase | +344.6K | $4.54 | +$1.56M | +12.0%3.21M after | |
| Mar 29, 2023 (view filing) | Mar 27-28 | 2 days | Hopfner Robert LorneDirector | PPurchase | +207.8K | $4.05 | +$841.1K | +7.8%2.87M after | 2 lots |
| Dec 19, 2022 (view filing) | Dec 15 | 4 days | Bjarke Henric BjornSVP, COO | PPurchase | +21.5K | $1.39 | +$29.9K | +25.6%105.4K after | |
| Apr 21, 2022 (view filing)6:04 PM ET | Apr 19 | 2 days | Enright Patrick G and 3 others10% Owner | PPurchase | +1.35M | $3.69 | +$5.00M | +48.1%4.17M after | |
| Apr 20, 2022 (view filing)6:22 PM ET | Apr 19 | 1 day | Pivotal bioVenture Partners Fund I, L.P. and 2 othersDirector | PPurchase | +1.07M | $3.69 | +$3.95M | +67.2%2.66M after | Duplicate filing |
Top 10 13F holders, Q2 2025
The largest institutional positions in Inozyme Pharma, Inc. at the end of Q2 2025; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beryl Capital Management LLC | 6,321,584 | $25.3M | 3.81% | +6,321,584 | New |
| Pivotal bioVenture Partners Investment Advisor LLC | 4,494,851 | $18.0M | 11.14% | 00.0% | Unchanged |
| Glazer Capital, LLC | 4,330,220 | $17.3M | 0.62% | +4,330,220 | New |
| Sofinnova Investments, Inc. | 4,280,308 | $17.1M | 1.16% | 00.0% | Unchanged |
| Oddo BHF Asset Management SAS | 3,200,000 | $12.8M | 0.49% | +3,200,000 | New |
| Trium Capital LLP | 3,173,454 | $12.7M | 3.16% | +3,173,454 | New |
| BlackRock, Inc. | 2,663,678 | $10.7M | 0.00% | −1,081,439−28.9% | Reduced |
| Vanguard Group Inc | 2,498,649 | $9.99M | 0.00% | −259,829−9.4% | Reduced |
| NEA Management Company, LLC | 2,437,689 | $9.75M | 0.73% | 00.0% | Unchanged |
| Alpine Associates Management Inc. | 2,188,100 | $8.75M | 0.47% | +2,188,100 | New |
Holders of 5% or more of INZY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Inozyme Pharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Glazer Capital, LLC | 13G | 6.59%4.25M shares | New | Jun 4, 20251 filing | Jun 4, 2025 | SEC |